Allos Therapeutics anticipates a January commercial launch for Folotyn, the first and only drug currently approved by the FDA for relapsing or refractory peripheral T-cell lymphoma (rrPTCL). A ...
CAMBRIDGE, Mass., Aug. 21, 2025 /PRNewswire/ -- Allos Pharma Inc., announces key milestones advancing its mission to deliver effective treatments for Autism Spectrum Disorder (ASD), Fragile X Syndrome ...
WESTMINSTER, Colo.--(BUSINESS WIRE)--Allos Therapeutics, Inc. (Nasdaq: ALTH) announced today that the Agreement and Plan of Merger and Reorganization ("the Merger Agreement") entered into by and among ...
Novel use of Causal AI revives long-stalled development pathways across complex generics and next-generation medicines for chronic disease Allos bends the cost-risk curve of drug development and ...
Spectrum Pharmaceuticals (NASDAQ: SPPI - News) and Allos Therapeutics, Inc. (NASDAQ: ALTH - News) today announced that they have signed a definitive agreement under which Spectrum will acquire all of ...
Under the collaboration, Allos will receive an upfront payment of $50 million and potential regulatory and commercial progress- and sales-dependent milestone payments of up to $310.5 million. Allos is ...
TEL AVIV (MarketWatch) -- Allos Therapeutics Inc., the Westminster, Colo., biopharma focused on cancer drugs, agreed to be acquired by Spectrum Pharmaceuticals Inc. for $1.82 cash plus a contigent ...
Allos Ventures, an Indianapolis-based venture capital firm focused on Midwest technology companies, announced Tuesday that it has raised $40 million for its latest fund, Allos III, and has begun ...
BANGALORE, Sept 25 (Reuters) - Allos Therapeutics said U.S. health regulators granted accelerated approval for its drug Folotyn to treat one of the most deadly and aggressive types of white blood cell ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results